Reference health

Hepatitis C: a clinical review

https://doi.org/10.1111/j.1601-0825.2007.01419.x
CiteStamped reference-health badge
33/33 checkable references clean · checked 2026-07-23

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

The 33 checked references that resolve
resolves10.1053/jhep.2002.36808
Therapy of acute hepatitis C
resolves10.1056/NEJM199908193410802
The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994
resolves10.1053/jhep.2002.36386
Treatment of patients with hepatitis C and normal serum aminotransferase levels
resolves10.1053/jhep.2002.36798
Monitoring of viral levels during therapy of hepatitis C
resolves10.1053/he.2000.5762
Natural history of hepatitis C: Its impact on clinical management
resolves10.1053/jhep.2002.36228
Optimal therapy of hepatitis C
resolves10.1053/j.gastro.2005.11.010
American Gastroenterological Association Technical Review on the Management of Hepatitis C
resolves10.1111/j.1572-0241.2005.00253.x
Response of Hepatitis C Genotype-4 Naive Patients to 24 Weeks of Peg-Interferon-alpha2b/Ribavirin or Induction-Dose Interferon-alpha2b/Ribavirin/Amantadine: A Non-Randomized Controlled Study
resolves10.1053/gast.1997.v112.pm9024300
Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
resolves10.1053/j.gastro.2004.09.014
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
resolves10.1038/nature04082
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
resolves10.1002/hep.1840360730
Side effects of therapy of hepatitis C and their management
resolves10.1056/NEJMoa020047
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
resolves10.1016/S0016-5085(03)00668-1
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance1 1The Bundesministerium für Bildung und Forschung and the European Union, as sponsors of the study, had no role in study design, data collection, analysis, or interpretation or in the writing and the decision to submit the report for publication.
resolves10.7326/0003-4819-140-5-200403020-00010
Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C
resolves10.1053/jhep.2003.50019
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load
resolves10.1002/hep.1840360704
Course and outcome of hepatitis C
resolves10.1056/NEJMct061675
Peginterferon and Ribavirin for Chronic Hepatitis C
resolves10.1002/hep.510290424
The Long–Term Outcomes of Patients With Compensated Hepatitis C Virus-Related Cirrhosis and History of Parenteral Exposure in the United States
resolves10.1002/hep.20266
Pegylated interferon α therapy in acute hepatitis C: Relation to hepatitis C virus-specific T cell response kinetics
resolves10.1053/j.gastro.2006.01.034
Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response
resolves10.1055/s-2005-864781
The Liver Biopsy in Chronic Hepatitis C: A View from the Other Side of the Microscope
resolves10.7326/0003-4819-132-4-200002150-00008
Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C
resolves10.1002/hep.20563
High‐dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C†
resolves10.1038/nature04077
Unravelling hepatitis C virus replication from genome to function
resolves10.1016/S0140-6736(01)06102-5
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
resolves10.1053/gast.2002.35950
Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
resolves10.1053/j.gastro.2007.03.014
Treatment of Hepatitis C: Don’t Put All Your Eggs in One Basket!
resolves10.1016/j.cld.2006.08.026
The Economics of Hepatitis C Virus
resolves10.1002/hep.20119
Diagnosis, management, and treatment of hepatitis C†
resolves10.1016/j.cld.2005.05.003
Natural History of Hepatitis C
resolves10.1055/s-2000-9506
Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends
resolves10.1002/hep.21043
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1111/j.1601-0825.2007.01419.x"><img src="https://citestamp.com/citestamped/10.1111/j.1601-0825.2007.01419.x/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1111/j.1601-0825.2007.01419.x/badge.svg)](https://citestamp.com/citestamped/10.1111/j.1601-0825.2007.01419.x)